1 jan 2007 ano - Food and Drug Administration Amendments Act of 2007

Descrição:

Specifically authorized FDA to require manufacturers post-marketing clinical studies to monitor for risks infected during the pre-market approval process
Also required REMS programs where necessary. What is a REMS program?

Adicionado na linha do tempo:

Data: